SCHEMBL936624

SCHEMBL936624

COc1cccc(C2CO2)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 4/20 0.54
HTR2A P28223 2/20 0.54
HTR2B P41595 2/20 0.54
LMNA P02545 1/20 0.54
CYP19A1 P11511 1/20 0.49
DRD2 P14416 1/20 0.49
TSHR P16473 1/20 0.48
KDM1A O60341 1/20 0.46
RCOR1 Q9UKL0 1/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
GAA P10253 1/20 0.46
KMT2A Q03164 1/20 0.46
PARP1 P09874 1/20 0.46
DDB1 Q16531 1/20 0.45
CRBN Q96SW2 1/20 0.45
GID4 Q8IVV7 1/20 0.45
ACHE P22303 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6493903 1.00 HTR2C (0.54) HTR2CHTR2AHTR2BLMNACYP19A1
SCHEMBL7784267 1.00 HTR2C (0.54) HTR2CHTR2AHTR2BLMNACYP19A1
SCHEMBL27301212 0.88 LMNA (0.48) HTR2CHTR2AHTR2BLMNACYP19A1
SCHEMBL22041291 0.87 LMNA (0.47) HTR2CHTR2AHTR2BLMNACYP19A1
SCHEMBL12186581 0.83 DRD2 (0.47) HTR2CHTR2AHTR2BLMNACYP19A1
SCHEMBL2599529 0.83 DRD2 (0.47) HTR2CHTR2AHTR2BLMNACYP19A1
SCHEMBL15154667 0.83 DRD2 (0.47) HTR2CHTR2AHTR2BLMNACYP19A1
SCHEMBL12186432 0.83 DRD2 (0.47) HTR2CHTR2AHTR2BLMNACYP19A1
SCHEMBL12186541 0.83 DRD2 (0.47) HTR2CHTR2AHTR2BLMNACYP19A1
SCHEMBL20262047 0.83 DRD2 (0.47) HTR2CHTR2AHTR2BLMNACYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119708491-A Polydisulfide polymer material containing hydroxy ester group and preparation method thereof 衢州化工新材料创新研究院 2025-03-28 CN claimed
JP-2004502669-A 2004-01-29 JP claimed
EP-1353898-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2003-10-22 EP claimed
WO-2002002512-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-01-10 WO claimed
CN-119708491-A Polydisulfide polymer material containing hydroxy ester group and preparation method thereof 衢州化工新材料创新研究院 2025-03-28 CN disclosed
EP-3202401-B1 PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CIRIUS THERAPEUTICS INC (US) 2019-10-23 EP disclosed
US-10131655-B2 Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists DR. REDDY'S LABORATORIES, LTD. (IN) 2018-11-20 US disclosed
EP-2822928-B1 SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS Dr Reddys Laboratories Ltd (IN) 2018-11-14 EP disclosed
EP-2513070-B1 PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES CIRIUS THERAPEUTICS INC (US) 2017-11-08 EP disclosed
EP-3202401-A1 PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Octeta Therapeutics, LLC (US) 2017-08-09 EP disclosed
US-20170001998-A1 SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS DR. REDDY'S LABORATORIES, LTD. (IN) 2017-01-05 US disclosed
EP-2512470-B1 PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OCTETA THERAPEUTICS LLC (US) 2016-11-30 EP disclosed
US-4427676-A Thiomorpholine derivatives JOHN WYETH & BROTHER LTD. (GB) 1984-01-24 US disclosed
EP-0002327-B1 PHARMACOLOGICALLY ACTIVE 6-LOWER ALKYL-7,8-DIHYDROXY-1-PHENYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES, METHOD OF PREPARING THEM AND INTERMEDIATES SMITHKLINE BECKMAN CORPORATION (US) 1982-08-04 EP disclosed
US-4342686-A Intermediates for preparing 6-lower alkyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines SMITHKLINE CORPORATION (US) 1982-08-03 US disclosed
US-4265889-A DOPAMINERGIC, HYPOTENSIVE SMITHKLINE CORPORATION (US) 1981-05-05 US disclosed
US-4206210-A PARKINSON'S DISEASE SMITHKLINE CORPORATION (US) 1980-06-03 US disclosed
EP-0002327-A1 Pharmacologically active 6-lower alkyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines, method of preparing them and intermediates SMITHKLINE BECKMAN CORPORATION (US) 1979-06-13 EP disclosed
US-4011319-A STIMULATING DOPAMINE RECEPTORS, RENAL VASODILATORS, DIURETICS SMITHKLINE CORPORATION (US) 1977-03-08 US disclosed
US-4005212-A ANTIDEPRESSANT, ANOREXIGENIC, PSYCHOENERGIZING, 2-PHENYL-2,3,5,6-TETRAHYDROIMIDAZO(2,1-B)THIAZOLE RHONE-POULENC S.A. (FR) 1977-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170001998-A1 SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS OPRK1, OPRL1, OPRD1 HTR2C 147/4885HTR2A 328/4885HTR2B 317/4885
US-10131655-B2 Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists OPRK1, OPRL1, OPRD1 HTR2C 147/4885HTR2A 328/4885HTR2B 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.